Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Celularity Inc (CELU)

Celularity Inc (CELU)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 54,083
  • Shares Outstanding, K 21,985
  • Annual Sales, $ 22,770 K
  • Annual Income, $ -196,300 K
  • EBIT $ -19 M
  • EBITDA $ 103 M
  • 60-Month Beta 0.51
  • Price/Sales 2.17
  • Price/Cash Flow 0.30
  • Price/Book 1.78

Options Overview Details

View History
  • Implied Volatility 230.53% ( -16.00%)
  • Historical Volatility 285.02%
  • IV Percentile 58%
  • IV Rank 19.17%
  • IV High 1,162.55% on 12/22/23
  • IV Low 9.52% on 07/15/24
  • Put/Call Vol Ratio 0.09
  • Today's Volume 75
  • Volume Avg (30-Day) 479
  • Put/Call OI Ratio 0.15
  • Today's Open Interest 1,161
  • Open Int (30-Day) 1,768

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/24
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year -2.20
  • Growth Rate Est. (year over year) +45,509.09%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.30 +113.08%
on 10/31/24
5.22 -46.93%
on 11/07/24
+0.26 (+10.36%)
since 10/18/24
3-Month
1.30 +113.08%
on 10/31/24
5.22 -46.93%
on 11/07/24
-0.29 (-9.37%)
since 08/16/24
52-Week
1.30 +113.08%
on 10/31/24
7.97 -65.24%
on 03/11/24
+0.67 (+32.03%)
since 11/17/23

Most Recent Stories

More News
Celularity Inc. Resolves Nasdaq Compliance Issue, Continues Trading on Nasdaq Stock Market

Celularity Inc. resolved its Nasdaq compliance issue, ensuring continued listing after curing filing delinquencies.Quiver AI SummaryCelularity Inc. announced that its hearing regarding non-compliance with...

CELU : 2.77 (+12.60%)
Celularity Inc. Announces Resolution of Nasdaq Listing Compliance Matter

CELU : 2.77 (+12.60%)
CELUW : 0.0250 (unch)
Celularity Raises Full Year 2024 Guidance as Expected Net Sales Through October Reach $44.4 Million

CELU : 2.77 (+12.60%)
CELUW : 0.0250 (unch)
Celularity Files Appeal Request and Amended Compliance Plan with Nasdaq Hearings Panel

CELU : 2.77 (+12.60%)
CELUW : 0.0250 (unch)
Celularity Provides Corporate Update

CELU : 2.77 (+12.60%)
CELUW : 0.0250 (unch)
Celularity Inc. Receives Notice from Nasdaq; Confirms Intention to File an Appeal

CELU : 2.77 (+12.60%)
CELUW : 0.0250 (unch)
Celularity Expands Advanced Biomaterial Product Commercial Portfolio with Acquisition of Rebound™ Product from Sequence LifeScience, Inc.

CELU : 2.77 (+12.60%)
CELUW : 0.0250 (unch)
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Is Investigating Celularity Inc. for Potential Breaches of Fiduciary Duty By Its Board of Directors

/PRNewswire/ -- Purcell & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of...

CELU : 2.77 (+12.60%)
CELULARITY ANNOUNCES $45 MILLION PURCHASE ORDER, FIRST MIDDLE EAST PRIVATE LABEL AGREEMENT FOR CELULARITY'S HALAL-CERTIFIED BIOMATERIAL PRODUCTS

/PRNewswire/ -- Celularity Inc. (Nasdaq: CELU) (Celularity), a biotechnology company developing placental-derived allogeneic cell therapies and biomaterial...

CELU : 2.77 (+12.60%)
Celularity Announces Agreement with AD Ports Group for Exclusive Product Distribution in Various Territories in the GCC and Egypt

/PRNewswire/ -- Celularity Inc. (Nasdaq: CELU) ("Celularity"), a biotechnology company developing placental-derived allogenic cell therapies and biomaterial...

CELU : 2.77 (+12.60%)

Business Summary

Celularity Inc. is a clinical stage biotechnology company. It involved in cellular medicine by developing off-the-shelf placental-derived allogeneic cell therapies, including unmodified NK cells, genetically-modified NK cells, T cells engineered with a CAR and mesenchymal-like adherent stromal cells...

See More

Key Turning Points

3rd Resistance Point 3.72
2nd Resistance Point 3.34
1st Resistance Point 3.05
Last Price 2.77
1st Support Level 2.38
2nd Support Level 2.00
3rd Support Level 1.71

See More

52-Week High 7.97
Fibonacci 61.8% 5.42
Fibonacci 50% 4.63
Fibonacci 38.2% 3.85
Last Price 2.77
52-Week Low 1.30

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar